Progress and Challenges of Amniotic Fluid Derived Stem Cells in Therapy of Ischemic Heart Disease
Cardiovascular disease is the leading cause of deaths worldwide, claiming an estimated total of 17.9 million lives each year, of which one-third of the people are under the age of 70 years. Since adult cardiomyocytes fail to regenerate, the heart loses the ability to repair itself after an injury, m...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/1/102 |
| _version_ | 1797543638014623744 |
|---|---|
| author | Yi-Hsien Fang Saprina P. H. Wang Hsien-Yuan Chang Pei-Jung Yang Ping-Yen Liu Yen-Wen Liu |
| author_facet | Yi-Hsien Fang Saprina P. H. Wang Hsien-Yuan Chang Pei-Jung Yang Ping-Yen Liu Yen-Wen Liu |
| author_sort | Yi-Hsien Fang |
| collection | DOAJ |
| description | Cardiovascular disease is the leading cause of deaths worldwide, claiming an estimated total of 17.9 million lives each year, of which one-third of the people are under the age of 70 years. Since adult cardiomyocytes fail to regenerate, the heart loses the ability to repair itself after an injury, making patients with heart disease suffer from poor prognosis. Pluripotent stem cells have the ability to differentiate into cardiomyocytes in vitro through a well-established process, which is a new advancement in cardiac regeneration therapy. However, pluripotent stem cell-derived cardiomyocytes have certain drawbacks, such as the risk of arrhythmia and immune incompatibility. Thus, amniotic fluid stem cells (AFSCs), a relatively novel source of stem cells, have been exploited for their ability of pluripotent differentiation. In addition, since AFSCs are weakly positive for the major histocompatibility class II molecules, they may have high immune tolerance. In summary, the possibility of development of cardiomyocytes from AFSCs, as well as their transplantation in host cells to produce mechanical contraction, has been discussed. Thus, this review article highlights the progress of AFSC therapy and its application in the treatment of heart diseases in recent years. |
| first_indexed | 2024-03-10T13:48:28Z |
| format | Article |
| id | doaj.art-716547888b5140e19c3bc1496588173a |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T13:48:28Z |
| publishDate | 2020-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-716547888b5140e19c3bc1496588173a2023-11-21T02:23:15ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-12-0122110210.3390/ijms22010102Progress and Challenges of Amniotic Fluid Derived Stem Cells in Therapy of Ischemic Heart DiseaseYi-Hsien Fang0Saprina P. H. Wang1Hsien-Yuan Chang2Pei-Jung Yang3Ping-Yen Liu4Yen-Wen Liu5Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70457, TaiwanInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70457, TaiwanInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70457, TaiwanInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70457, TaiwanInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70457, TaiwanInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70457, TaiwanCardiovascular disease is the leading cause of deaths worldwide, claiming an estimated total of 17.9 million lives each year, of which one-third of the people are under the age of 70 years. Since adult cardiomyocytes fail to regenerate, the heart loses the ability to repair itself after an injury, making patients with heart disease suffer from poor prognosis. Pluripotent stem cells have the ability to differentiate into cardiomyocytes in vitro through a well-established process, which is a new advancement in cardiac regeneration therapy. However, pluripotent stem cell-derived cardiomyocytes have certain drawbacks, such as the risk of arrhythmia and immune incompatibility. Thus, amniotic fluid stem cells (AFSCs), a relatively novel source of stem cells, have been exploited for their ability of pluripotent differentiation. In addition, since AFSCs are weakly positive for the major histocompatibility class II molecules, they may have high immune tolerance. In summary, the possibility of development of cardiomyocytes from AFSCs, as well as their transplantation in host cells to produce mechanical contraction, has been discussed. Thus, this review article highlights the progress of AFSC therapy and its application in the treatment of heart diseases in recent years.https://www.mdpi.com/1422-0067/22/1/102amniotic fluid stem cellspluripotent stem cellsstem cell therapycardiovascular diseasesregenerative therapy |
| spellingShingle | Yi-Hsien Fang Saprina P. H. Wang Hsien-Yuan Chang Pei-Jung Yang Ping-Yen Liu Yen-Wen Liu Progress and Challenges of Amniotic Fluid Derived Stem Cells in Therapy of Ischemic Heart Disease International Journal of Molecular Sciences amniotic fluid stem cells pluripotent stem cells stem cell therapy cardiovascular diseases regenerative therapy |
| title | Progress and Challenges of Amniotic Fluid Derived Stem Cells in Therapy of Ischemic Heart Disease |
| title_full | Progress and Challenges of Amniotic Fluid Derived Stem Cells in Therapy of Ischemic Heart Disease |
| title_fullStr | Progress and Challenges of Amniotic Fluid Derived Stem Cells in Therapy of Ischemic Heart Disease |
| title_full_unstemmed | Progress and Challenges of Amniotic Fluid Derived Stem Cells in Therapy of Ischemic Heart Disease |
| title_short | Progress and Challenges of Amniotic Fluid Derived Stem Cells in Therapy of Ischemic Heart Disease |
| title_sort | progress and challenges of amniotic fluid derived stem cells in therapy of ischemic heart disease |
| topic | amniotic fluid stem cells pluripotent stem cells stem cell therapy cardiovascular diseases regenerative therapy |
| url | https://www.mdpi.com/1422-0067/22/1/102 |
| work_keys_str_mv | AT yihsienfang progressandchallengesofamnioticfluidderivedstemcellsintherapyofischemicheartdisease AT saprinaphwang progressandchallengesofamnioticfluidderivedstemcellsintherapyofischemicheartdisease AT hsienyuanchang progressandchallengesofamnioticfluidderivedstemcellsintherapyofischemicheartdisease AT peijungyang progressandchallengesofamnioticfluidderivedstemcellsintherapyofischemicheartdisease AT pingyenliu progressandchallengesofamnioticfluidderivedstemcellsintherapyofischemicheartdisease AT yenwenliu progressandchallengesofamnioticfluidderivedstemcellsintherapyofischemicheartdisease |